By Josh Beckerman
CureVac NV shares were recently down 12%, to $39.99, three days after it said it would end development of its first-generation Covid-19 vaccine candidate.
According to a Reuters report citing German newspaper Rheinische Post, Bayer AG and CureVac terminated a vaccine production agreement.
On Thursday, CureVac shareholder Dievini Hopp Biotech Holding GmbH filed an amended Form 13-D with the U.S. Securities and Exchange Commission. The amendment reflects an internal reorganization related to share ownership and the transfer of some shares to CureVac in connection with an investment and shareholders' agreement.
The company said in June that the first-generation CVnCoV vaccine was 48% effective in providing protection against Covid-19 of any severity, a lower figure than the vaccines approved in the U.S. In August, CureVac reported favorable preclinical data for a second-generation vaccine candidate.
Write to Josh Beckerman at firstname.lastname@example.org
(END) Dow Jones Newswires